Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Genotoxicity of 2-(3-Chlorobenzyloxy)-6-(piperazinyl)pyrazine, a Novel 5-Hydroxytryptamine2c Receptor Agonist for the Treatment of Obesity: Role of Metabolic Activation

Amit S. Kalgutkar, Deepak K. Dalvie, Jiri Aubrecht, Evan B. Smith, Stephanie L. Coffing, Jennifer R. Cheung, Chandra Vage, Mary E. Lame, Phoebe Chiang, Kim F. McClure, Tristan S. Maurer, Richard V. Coelho Jr., Victor F. Soliman and Klaas Schildknegt
Drug Metabolism and Disposition June 2007, 35 (6) 848-858; DOI: https://doi.org/10.1124/dmd.106.013649
Amit S. Kalgutkar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deepak K. Dalvie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiri Aubrecht
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evan B. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie L. Coffing
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer R. Cheung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandra Vage
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary E. Lame
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Phoebe Chiang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim F. McClure
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tristan S. Maurer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard V. Coelho Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor F. Soliman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaas Schildknegt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

2-(3-Chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine (3) is a potent and selective 5-HT2C agonist that exhibits dose-dependent inhibition of food intake and reduction in body weight in rats, making it an attractive candidate for treatment of obesity. However, examination of the genotoxicity potential of 3 in the Salmonella Ames assay using tester strains TA98, TA100, TA1535, and TA1537 revealed a metabolism (rat S9/NADPH)- and dose-dependent increase of reverse mutations in strains TA100 and TA1537. The increase in reverse mutations was attenuated upon coincubation with methoxylamine and glutathione. The irreversible and concentration-dependent incorporation of radioactivity in calf thymus DNA after incubations with [14C]3 in the presence of rat S9/NADPH suggested that 3 was bioactivated to a reactive intermediate that covalently bound DNA. In vitro metabolism studies on 3 with rat S9/NADPH in the presence of methoxylamine and cyanide led to the detection of amine and cyano conjugates of 3. The mass spectrum of the amine conjugate was consistent with condensation of amine with an aldehyde metabolite derived from hydroxylation of the secondary piperazine nitrogen-α-carbon bond. The mass spectrum of the cyano conjugate suggested a bioactivation pathway involving N-hydroxylation of the secondary piperazine nitrogen followed by two-electron oxidation to generate an electrophilic nitrone, which reacted with cyanide. The 3-chlorobenzyl motif in 3 was also bioactivated via initial aromatic ring hydroxylation followed by elimination to a quinone-methide species that reacted with glutathione or with the secondary piperazine ring nitrogen in 3 and its monohydroxylated metabolite(s). The metabolism studies described herein provide a mechanistic basis for the mutagenicity of 3.

Footnotes

  • doi:10.1124/dmd.106.013649.

  • ABBREVIATIONS: 5-HT, 5-hydroxytryptamine, serotonin; 3, 2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine; NMR, nuclear magnetic resonance; 5, 6-(3-chlorobenzyloxy)-N-(2-aminoethyl)pyrazin-2-amine; 1, tert-butyl-4-(6-chloropyrazin-2-yl)piperazine-1-carboxylate; MS, mass spectrometry; 2, tert-butyl-4-(6-(3-chlorobenzyloxy)pyrazin-2-yl)piperazine-1-carboxylate; 4, 2-(3-chlorobenzyloxy)-6-chloropyrazine; DMSO, dimethyl sulfoxide; LC-MS/MS, liquid chromatography tandem mass spectrometry; CID, collision-induced dissociation; MRM, multiple reaction monitoring; Rt, retention time; P450, cytochrome P450.

    • Received November 1, 2006.
    • Accepted March 2, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 35 (6)
Drug Metabolism and Disposition
Vol. 35, Issue 6
1 Jun 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Genotoxicity of 2-(3-Chlorobenzyloxy)-6-(piperazinyl)pyrazine, a Novel 5-Hydroxytryptamine2c Receptor Agonist for the Treatment of Obesity: Role of Metabolic Activation
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Genotoxicity of 2-(3-Chlorobenzyloxy)-6-(piperazinyl)pyrazine, a Novel 5-Hydroxytryptamine2c Receptor Agonist for the Treatment of Obesity: Role of Metabolic Activation

Amit S. Kalgutkar, Deepak K. Dalvie, Jiri Aubrecht, Evan B. Smith, Stephanie L. Coffing, Jennifer R. Cheung, Chandra Vage, Mary E. Lame, Phoebe Chiang, Kim F. McClure, Tristan S. Maurer, Richard V. Coelho, Victor F. Soliman and Klaas Schildknegt
Drug Metabolism and Disposition June 1, 2007, 35 (6) 848-858; DOI: https://doi.org/10.1124/dmd.106.013649

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Genotoxicity of 2-(3-Chlorobenzyloxy)-6-(piperazinyl)pyrazine, a Novel 5-Hydroxytryptamine2c Receptor Agonist for the Treatment of Obesity: Role of Metabolic Activation

Amit S. Kalgutkar, Deepak K. Dalvie, Jiri Aubrecht, Evan B. Smith, Stephanie L. Coffing, Jennifer R. Cheung, Chandra Vage, Mary E. Lame, Phoebe Chiang, Kim F. McClure, Tristan S. Maurer, Richard V. Coelho, Victor F. Soliman and Klaas Schildknegt
Drug Metabolism and Disposition June 1, 2007, 35 (6) 848-858; DOI: https://doi.org/10.1124/dmd.106.013649
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Endogenous substrates of rat organic cation transporters
  • Catabolism and Metabolism of ABBV-011, a Calicheamicin ADC
  • Gadoxetate-enhanced MRI and FXR in benign tumours
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics